Clinical Trials Directory

Futility Study of Deferoxamine in Intracerebral Hemorrhage

The main purpose of this study is to determine whether treatment with deferoxamine mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for brain hemorrhage.

Stanford is now accepting new patients for this trial. Please contact Stephanie Kemp at (650) 723-4481 for more information.



  • drug : Normal saline
  • drug : Deferoxamine

Phase: Phase 2


Ages Eligible For Study:

18 Years - 80 Years

Inclusion Criteria

1. Age ? 18 and ? 80 years 2. The diagnosis of ICH is confirmed by brain CT scan 3. NIHSS score ? 6 and GCS > 6 upon presentation 4. The first dose of the study drug can be administered within 24h of ICH symptom onset 5. Functional independence prior to ICH, defined as pre-ICH mRS ? 1 6. Signed and dated informed consent is obtained.

External Links

Explore related trials

Contact information

Primary Contact:

Stephanie Kemp (650) 723-4481

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: